BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35331553)

  • 1. Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
    Castro PP; de Perrot M; Chua YC; Bezjak A; Leighl N; Darling G; Pierre A; Yasufuku K; Cypel M; Waddell T; Donahoe L; Yeung J; Keshavjee S
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):629-636. PubMed ID: 35331553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended surgical resection in stage III non-small cell lung cancer.
    Hillinger S; Weder W
    Front Radiat Ther Oncol; 2010; 42():115-121. PubMed ID: 19955797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of surgery in N2 NSCLC: pros.
    Shien K; Toyooka S
    Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis.
    Li D; Li W; Pang Y; Xu L; Xu X
    Medicine (Baltimore); 2022 Jul; 101(28):e29580. PubMed ID: 35839033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multimodal treatment of non small cell lung cancer].
    Stoelben E; Digel W; Henke M; Passlick B
    Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
    Furrer K; Weder W; Eboulet EI; Betticher D; Pless M; Stupp R; Krueger T; Perentes JY; Schmid RA; Lardinois D; Furrer M; Früh M; Peters S; Curioni-Fontecedro A; Stahel RA; Rothschild SI; Hayoz S; Opitz I
    J Thorac Cardiovasc Surg; 2022 Dec; 164(6):1587-1602.e5. PubMed ID: 35688713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical therapeutic strategy for non-small cell lung cancer with mediastinal lymph node metastasis (N2).
    Ma Q; Liu D; Guo Y; Shi B; Song Z; Tian Y
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):342-8. PubMed ID: 20677562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
    Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of upfront surgery in patients with resectable pathological N2 non-small-cell lung cancer.
    Yun JK; Bok JS; Lee GD; Kim HR; Kim YH; Kim DK; Park SI; Choi S
    Eur J Cardiothorac Surg; 2020 Jul; 58(1):59-69. PubMed ID: 32155245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Is there a place for surgical management in stage IIIA N2 non-small cell lung cancer?].
    Pagès PB; Pforr A; Delpy JP; Abou Hanna H; Bernard A
    Rev Mal Respir; 2015 May; 32(5):485-92. PubMed ID: 25498767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should surgery be part of the multimodality treatment for stage IIIB non-small cell lung cancer?
    Collaud S; Provost B; Besse B; Fabre D; Le Chevalier T; Mercier O; Mussot S; Fadel E
    J Surg Oncol; 2018 Jun; 117(7):1570-1574. PubMed ID: 29573419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement.
    Tieu BH; Sanborn RE; Thomas CR
    Thorac Surg Clin; 2008 Nov; 18(4):403-15. PubMed ID: 19086609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
    Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.